Table 1.
Type of first antiretroviral treatment, by year in which treatment started
| Year started | Mono/double antiretroviral | 3+ (NRTI ± PI – NNRTI)* | 3+ (NRTI+NNRTI – PI)† | 3+(NNRTI+PI ± NRTI)‡ | ||
|---|---|---|---|---|---|---|
| d4T/3TC/NVP | 3TC/ZDV/NVP | Others | ||||
|
| ||||||
| ≤1999 | 281 (72%) | 101 (26%) | 6 (2%) | 0 (0%) | ||
|
|
||||||
| 1 (17%) | 1 (17%) | 4 (66%) | ||||
|
|
||||||
| 2000 | 48 (29%) | 27 (16%) | 89 (54%) | 0 (0%) | ||
|
|
||||||
| 22 (25%) | 8 (9%) | 59 (66%) | ||||
|
|
||||||
| 2001 | 38 (17%) | 39 (18%) | 140 (64%) | 3 (1%) | ||
|
|
||||||
| 33 (24%) | 19 (14%) | 88 (63%) | ||||
|
|
||||||
| 2002 | 31 (8%) | 36 (10%) | 297 (81%) | 3 (1%) | ||
|
|
||||||
| 140 (47%) | 30 (10%) | 127 (43%) | ||||
|
|
||||||
| 2003 | 30 (7%) | 21 (4%) | 403 (88%) | 4 (1%) | ||
|
|
||||||
| 174 (43%) | 50 (12%) | 179 (45%) | ||||
|
|
||||||
| 2004 | 15 (14%) | 6 (6%) | 81 (77%) | 3 (3%) | ||
|
|
||||||
| 34 (42%) | 12 (15%) | 35 (43%) | ||||
*
3+ (NRTI ± PI – NNRTI), three or more drugs including at least one nucleoside reverse transcriptase inhibitor (NRTI) and/or a protease inhibitor (PI), but without a nonnucleoside reverse transcriptase inhibitor (NNRTI).
†
3+ (NRTI + NNRTI – PI), three or more drugs including at least one NNRTI, but without a PI.
‡
3+ (NNRTI + PI ± NRTI), three or more drugs including at least one NNRTI and one PI, with or without an NRTI.
d4T, stavudine; 3TC, lamivudine; NVP, nevirapine; ZDV, zidovudine.